

To, June 5, 2020

National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400051

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 023.

Dear Sirs,

Scrip Code: 532926

Scrip Code: JYOTHYLAB

Sub: Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended March 31, 2020

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") and other applicable provisions, if any, we wish to inform you that the Board of Directors of the Company at its meeting held today through video conferencing, which commenced at 2:00 p.m. and concluded at 4:10 p.m. have approved the Audited Financial Results of the Company on Standalone and Consolidated basis for the quarter and year ended March 31, 2020.

Accordingly, we are enclosing herewith the following:

- a) Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2020;
- b) Auditors Report issued by M/s. B S R & Co. LLP, Statutory Auditors of the Company on the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2020; and
- c) Press Release by the Company in respect of its performance during the quarter and year ended March 31, 2020.

The report of M/s. B S R & Co. LLP, Statutory Auditors of the Company, is with the unmodified opinion with respect to the Audited Financial Results (Standalone and Consolidated) for the year ended March 31, 2020.

Jyothy Labs Limited

(Formerly known as Jyothy Laboratories Limited)

CIN: L24240MH1992PLC128651

'Ujala House', Ramkrishna Mandir Road, Kondivita, Andheri (East), Mumbai 400 059. Tel: +91 022-6689 2800 | Fax: +91 022-6689 2805

info@jyothy.com | www.jyothylabs.com



Further, on account of the on-going pandemic of COVID-19, SEBI vide its Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/48 dated March 26, 2020 and Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/79 dated May 12, 2020 has exempted publication of advertisements in newspapers, as required under Regulation 47 of the Listing Regulations for all the events scheduled till June 30, 2020. Accordingly, the Extract of the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2020 will not be published in any Newspapers by the Company.

The above Audited Financial Results for the quarter and year ended March 31, 2020 will however be available on the website of the Company i.e. www.jyothylabs.com

Kindly take the above on your record and disseminate the same for information of investors. Thanking you,

Yours faithfully,

For Jyothy Labs Limited (Formerly Known as Jyothy Laboratories Limited)

Shreyas Trivedi

Head – Legal & Company Secretary

Encl.: As above

BSR&Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus, Apollo Mills Compound N. M. Joshi Marg, Mahalaxmi Mumbai - 400 011 India Telephone +91 (22) 4345 5300 Fax +91 (22) 4345 5399

Independent Auditors' Report

To the Board of Directors of Jyothy Labs Limited

(formerly known as Jyothy Laboratories Limited)

Report on the audit of the Standalone Annual Financial Results

Opinion

We have audited the accompanying standalone annual financial results of Jyothy Labs Limited (formerly known as Jyothy Laboratories Limited) (hereinafter referred to as the "Company") for the year ended 31 March 2020, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:

- a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the year ended 31 March 2020.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our opinion on the Standalone annual financial results.



Jyothy Labs Limited

(formerly known as Jyothy Laboratories Limited)

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of standalone financial statements on whether the company has adequate internal financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls.

SRW

Jyothy Labs Limited

(formerly known as Jyothy Laboratories Limited)

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results (Continued)

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The standalone annual financial results include the results for the quarter ended 31 March 2020 being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No: 101248W/W-100022

Sreeja Morar

Membership No: 111410

UDIN- 20111410AAAABA3415

Mumbai 5 June 2020

BSR&Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus, Apollo Mills Compound N. M. Joshi Marg, Mahalaxmi Mumbai - 400 011 Telephone +91 (22) 4345 5300 Fax +91 (22) 4345 5399

Independent Auditors' Report

To the Board of Directors of Jyothy Labs Limited

(formerly known as Jyothy Laboratories Limited)

Report on the audit of the Consolidated Annual Financial Results

Opinion

We have audited the accompanying consolidated annual financial results of Jyothy Labs Limited (formerly known as Jyothy Laboratories Limited) (hereinafter referred to as the "Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group") for the year ended 31 March 2020, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate audited financial statements of the subsidiaries, the aforesaid consolidated annual financial results:

- a. include the annual financial results of the following subsidiaries
 - 1. Jyothy Fabricare Sevices Limited
 - 2. Jyothy Kallol Bangladesh Limited
 - 3. Snoways Laundrers and Drycleaners Private Limited
 - 4. Four Seasons Drycleaning Company Private Limited
 - 5. JFSL-JLL (JV)
- are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- c. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of consolidated net profit and other comprehensive income and other financial information of the Group for the year ended 31 March 2020.



Jyothy Labs Limited

(formerly known as Jyothy Laboratories Limited)

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the consolidated financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us along with the consideration of audit reports of the other auditors referred to in sub paragraph (a) of the "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion on the consolidated annual financial results.

Management's and Board of Directors' Responsibilities for the Consolidated Annual Financial Results

These consolidated annual financial results have been prepared on the basis of the consolidated annual financial statements.

The Holding Company's Management and the Board of Directors are responsible for the preparation and presentation of these consolidated annual financial results that give a true and fair view of the consolidated net profit and other comprehensive income and other financial information of the Group including in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Management and Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated annual financial results by the Management and the Directors of the Holding Company, as aforesaid.

In preparing the consolidated annual financial results, the Management and the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of each company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group is responsible for overseeing the financial reporting process of each company.

Jyothy Labs Limited

(formerly known as Jyothy Laboratories Limited)

Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of consolidated financial statements on whether the company has adequate internal financial controls with reference to consolidated financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the consolidated financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated annual financial results, including the disclosures, and whether the consolidated annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results of the entities within the Group to express an opinion on the consolidated annual financial results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated annual financial results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in para (a) of the section titled "Other Matters" in this audit report.

Jyothy Labs Limited

(formerly known as Jyothy Laboratories Limited)

Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results (Continued)

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated annual financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular No CIR/CFD/CMD1/44/2019 issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters

(a) The consolidated annual financial results include the audited financial results of four subsidiaries, whose financial statements reflect Group's share of total assets (before consolidation adjustments) of Rs. 2,039 lacs as at 31 March 2020, Group's share of total revenue (before consolidation adjustments) of Rs. 1,635 lacs and Group's share of total net profit after tax (before consolidation adjustments) of Rs. 107 lacs and Group's share of net cash inflows of Rs 145.32 lacs for the year ended on that date, as considered in the consolidated annual financial results, which have been audited by their respective independent auditors. The independent auditors' reports on financial statements of these entities have been furnished to us by the management and our opinion on the consolidated annual financial results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the reports of such auditors and the procedures performed by us as stated in the paragraph above.

One of the subsidiary which is located outside India whose financial statements have been prepared in accordance with accounting principles generally accepted in their country and which have been audited by another auditor under generally accepted auditing standards applicable in their country. The Company's management has converted the financial statement of such subsidiary located outside India from accounting principles generally accepted in their country to accounting principles generally accepted in India. We have audited these conversion adjustments made by the Company's management. Our opinion in so far as it relates to the balances and affairs of such subsidiary located outside India is based on the report of the other auditor and the conversion adjustments prepared by the management of the Company and audited by us.

Our opinion on the consolidated annual financial results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

(b) The consolidated annual financial results include the results for the quarter ended 31 March 2020 being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For BSR & Co. LLP

Chartered Accountants

Firm's Registration No: 101248W/W-100022

Sreeja Marar

Membership No: 111410

Mumbai 5 June 2020

UDIN- 20111410AAAAAZ5204

JYOTHY LABS LIMITED (FORMERLY KNOWN AS JYOTHY LABORATORIES LIMITED) (CIN: L24240MH1992PLC128651)

STATEMENT OF STANDALONE/CONSOLIDATED FINANCIAL RESULTS

FOR THE QUARTER AND YEAR ENDED MARCH 31, 2020

Registered Office: Ujala House, Ramakrishna Mandir Road, Kondivlta, Andheri East, Mumbai 400059.

(Rs in lacs)

	Standalone			or to t	Consolidated					
Particulars	Quarter ended		Year ended		Quarter ende			-	ended	
	31,03,2020	31.12.2019	31.03.2019	31.03.2020	31,03,2019	31.03.2020	31.12.2019		31.03.2020	31.03.201
	Audited (Note 7)	Unaudited	Audited (Note 7)	Audited	Audited	Audited (Note 7)	Unaudited	Audited (Note 7)	Audited	Audited
Revenue from operations	38,229	40,725	50,429	166,538	176,888	39,300	42,079	51,598	171,117	181,358
Other income	445	532	1,135	2,005	2,783	460	504	1,183	2,000	2,775
Total Income	38,674	41,257	51,564	168,543	179,671	39,760	42,583	52,781	173,117	184,133
Expenses										
(a) Cost of materials consumed	17,693	17,576	19,444	69,230	70,423	17,944	17,829	19,702	70,194	71,317
(b) Purchases of stock in trade	4,990	5,907	6,650	23,149	26,783	4,990	5,907	6,650	23,149	26,783
(c) Changes in inventories of finished goods, stock in	4,220	3,507	0,050	25,145	20,703	4,220	3,507	0,050	23,149	20,703
trade and work-in-progress	(1,547)	(2,169)	1,908	(3,178)	(1,025)	(1,595)	(2,163)	1,940	(3,251)	(1,029
(d) Employee benefits expense	4,592	5,212	4,883	20,032	18,860	5,057	5.705	5,342	21,933	20,763
(e) Finance cost	584	693	640	2,478	2,782	778	887	942	3,288	3,522
(f) Advertisement and sales promotion expense	3,465	2,445	3,139	11,993	10,933	3,559	2,522	3,229	12,271	11,269
	1,913	1,933	1,667	7,573	5,829	1,415	1,320	997		- D#00110
(g) Depreciation and amortisation expenses (h) Other expenses	5,020	5,246	6,147	20,328	22,336	5,289	5,648	6,605	5,292	3,057
	36,710	36,843	44,478	151,605	156,921	37,437	37,655	45,407	21,713 154,589	24,147
Total expenses Profit before tax and exceptional item	1,964	4,414	7,086	16,938	22,750	2,323	4,928	7,374	18,528	159,829 24,304
Exceptional item (Note 2)	1,704	4,414	7,000	378	22,730	2,343	4,320	1,5/4	378	24,304
Profit before tax	1,964	4,414	7,086	16,560	22,750	2,323	4,928	7,374	18,150	24,304
Tax expenses	(639)	160	381	790	3,433	(336)	4328	691		
Lax expenses Current lax	233	720	1,484	2,663	4,691	295	721		1,892	4,544
Adjustment of tax relating to earlier periods	233	/20	1,404	2,003	4,091	293	721	1,527	2,728	4,736
Deferred tax charge / (credit)	(872)	(560)	(1,103)	(1,873)	(1,258)	(631)	(295)	(840)	(836)	4
Net Profit for the period	2,603	4,254	6,705	15,770	19.317	2,659	4,502	-	16,258	(196
Other Comprehensive Income	2,003	4,454	8,705	15,770	19,517	2,039	4,502	6,683	10,258	19,760
(a) Items that will not be reclassified to profit or loss	(488)	22	(239)	(422)	(173)	(503)	22	(280)	(122)	(212
	(400)	22	(239)	(422)	(173)	(503)	22	(280)	(437)	(213
(b) Tax (expense)/benefit on items that will not be reclassified to profit or loss	171	(7)	84	148	61	171	/03	84	148	
(c) Items that will be reclassified to profit or loss	171	1/1	- 04	140	- 01	26	(8)	(3)	33	61
Other Comprehensive Income for the period	(317)	15	(155)	(274)	(112)	(306)	20	(199)	(256)	(124
Total Comprehensive Income for the period Non-Controlling Interest	2,286	4,269	6,550	15,496	19,205	2,353 (220)	4,522 (157)	6,484 (230)	16,002 (772)	19,636
Total Comprehensive Income after Non-Controlling				_		(220)	(137)	[230]	(112)	(752
Interest	2,286	4.269	6,550	15,496	19,205	2,573	4,679	6,714	16,774	20,388
Profit/(loss) attributable to :	2,200	4,203	0,000	13,490	17,405	21010	44072	0,/14	10,774	20,500
Owners of Jyothy Labs Limited						2,880	4,655	6,903	17.027	20,509
Non-Controlling Interest						(221)	(153)	(220)	(769)	(749
Other Comprehensive Income attributable to:						(221)	(155)	(440)	[102]	(743
Owners of Jyothy Labs Limited						(307)	24	(189)	(253)	(121
Non-Controlling Interest						(307)	(4)	(10)	(3)	(3
Total Comprehensive Income attributable to:						<u> </u>	(4)	(10)	(5)	13
Owners of Jyothy Labs Limited		_				2,573	4,679	6,714	16,774	20,388
Non-Controlling Interest						(220)	(157)	(230)	(772)	(752
ton commonly market		-				(220)	(137)	(230)	(112)	(132
Paid up equity share capital (Face value of Re 1/- each) Other equity	3,672	3,672	3,672	3,672 70,656	3,672 81,723	3,672	3,672	3,672	3,672 119,192	3,672 128,981
Earnings Per Share of face value Re 1/- each										
Basic earnings per share (Rs)	0.71	1.16	1.84	4,29	5.29	0.78	1.27	1 89	4.64	5,6
Diluted earnings per share (Rs)	0.71							1 89		5.6
	3.71	1.10	4,05	1.67	2 47	0.70	1.21	1 02	3,04	3.0
	Not	Not	Not			Not	Not	Not		

Notes :

- 1. The above audited financial results of the Company for the quarter and year ended March 31, 2020 were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on June 05, 2020
- 2. Exceptional item includes one time expenses related to change in brand identity of the Company including its logo and name
- 3. The Company has changed its name from Jyothy Laboratories Limited to Jyothy Labs Limited with effect from July 11, 2019 pursuant to the change of name certificate issued by the Ministry of Corporate Affairs.
- 4. The Company has adopted modified retrospective approach as per IND AS 116 Leases, effective from annual reporting period beginning April 1, 2019. This has resulted in recognizing right of use assets and corresponding lease liability of Rs,5,023.98 lacs and Rs,5,972.08 lacs as at April 1, 2019 in the standalone and consolidated balance sheet respectively. In the statement of profit and loss for the current period operating lease expenses has changed from rent to depreciation cost for the right of use assets and finance cost for interest accrued on lease liability. Due to this change current quarter profit before tax is lower by Rs.51.05 lacs (Rs.295.53 lacs full year) and Rs.62.75 lacs (Rs.348.92 lacs full year) in standalone and consolidated results respectively. To this extent, performance for the current period/year March 31, 2020 is not comparable with previous period results. 5. In view of lockdown due to the outbreak of COVID pandemic, the operations of the Company were temporarily disrupted at all manufacturing locations, warehouses and distributor godowns. While this has adversely impacted the sales in the month of March 2020, our product portfolio primarily comprises of Essential Hygiene goods which forms part of day to day household consumption sold from grocery chains, Since mid-April 2020, the Company has started resuming its operations in compliance with the directives issued by the Government authorities. In the short term, Company has adequate resources to sustain the impact of Covid-19. We do not foresee any material adverse impact in the medium to long term on the business. Based on our current assessment, no significant impact on carrying value on goodwill, inventory, trade receivables, intangible assets, investments and other financial assets is expected. The actual impact of global pandemic could be different from estimated, as the COVID scenario evolves in India. The company will continue to closely monitor any material changes to future economic conditions.
 6. The Board of Directors of the Company at its meeting held on March 12, 2020 had declared and paid an Interim dividend of Rs 3,00 per share (300% of the paid up share capital)
- The figures for the quarter ended March 31, 2020 and March 31, 2019 are the balancing figures between the audited figures in respect of the full financial year and unaudited

BS LIN

- published figures upto the third quarter for the respective years. Also the figures upto the the third quarter had been reviewed and not subject to audit. The consolidated financial results for the quarter and nine month ended December 31, 2018 were not subjected to limited review by the statutory auditors of the Company and are as prepared by the
- Previous period / year's figures have been regrouped/rearranged wherever necessary
- 9. For more details on results, visit investor center section of the Company's website at www.jyothylabs.com and financial result under corporates section of Stock Exchange's

Website at www nseindia com and www bseindia com

For and on behalf of the Board

DIN : 00571828

Place: Mumbai Date: June 05, 2020



JYOTHY LABS LIMITED (FORMERLY KNOWN AS JYOTHY LABORATORIES LIMITED) STATEMENT OF STANDALONE/CONSOLIDATED FINANCIAL RESULTS

Notes:

10. Statement of Assets and Liabilities :-

	Standalone Conso				
	As at March	As at March	Consolidated As at March As at March		
Particulars	31, 2020	31, 2019	31, 2020	CACHELL MAINTEN MANAGEMENT SPECIAL	
	Audited	Audited	Audited	31, 2019 Audited	
Assets	Addited	Audited	Audited	Audited	
Non-Current Assets					
Property, plant and equipment	26,999	27,151	30,536	20.000	
Capital work in progress	2,374	1,415		30,808	
Right-of-use assets	4,525	1	2,450	1,436	
Goodwill		10.200	5,158	# FO COO	
Other Intangible assets	10,288	10,288	78,633	78,633	
Financial assets	6,599	9,679	590	619	
Investment in subsidiaries	12.000	11100			
Other investments	13,929	14,192	-	-	
	3	3	3	3	
Loans	919	783	1,088	948	
Other financial assets	363	61	373	63	
Deferred tax assets (net)	9,622	7,601	10,270	9,281	
Income Tax assets (net)	992	160	1,235	407	
Other non-current assets	8,393	9,835	8,412	9,850	
	85,006	81,168	138,748	132,048	
Current assets					
Inventories	22,259	20,064	22,507	20,229	
Financial assets	1				
Investments		10,012	5	10,442	
Trade receivables	11,956	14,826	12,238	15,338	
Cash and cash equivalents	686	6,684	1,492	7,484	
Bank balances other than cash and cash equivalents	1,321	2,071	1,402	2,153	
Loans	671	(2)	55	46	
Other financial assets	316	638	316	638	
Other current assets	6,699	5,744	6,861	5,850	
	43,908	60,039	44,871	62,180	
	10,700	00,007	74,071	02,100	
Total Assets	128,914	141,207	183,619	194,228	
			100,022	17 11220	
Equity					
Equity Share Capital	3,672	3,672	3,672	3,672	
Other Equity	70,656	81,723	119,192	128,981	
Equity attributable to owners of Jyothy Labs Limited	74,328	85,395	122,864	132,653	
Non-controlling interests		- 0	(2,912)	(2,146)	
Total equity	74,328	85,395	119,952	130,507	
Liabilities					
Non-Current liabilities					
Financial Liabilities					
Borrowings		14	27	202	
Other financial liabilities	2,900		3,324	202	
Provisions	5,288	4,331	5,552	4,552	
Other non-current liabilities	303	354	303	354	
	8,491	4,685	9,206	5,108	
Current liabilities	0,471	4,003	7,200	5,108	
Financial Liabilities					
Borrowings	22,094	21.527	22.004	21.527	
Trade payables	22,094	21,537	22,094	21,537	
Total outstanding dues of micro enterprises and small enterprises	1,023	3,813	1,058	3,821	
Total outstanding dues of creditors other than micro enterprises and small	11,656	13,666	11.010	14000	
enterprises	11,030	13,000	11,918	14,062	
Other financial liabilities	3,715	3,773	11,718	10,799	
Other current liabilities	5,314	5,769	5,349	5,799	
Provisions	2,247	2,222	2,278	2,248	
Current Tax liabilities (net)	46	347	46	347	
	46,095	51,127	54,461	58,613	
			- HIVA	20,013	
Total liabilities	54,586	55,812	63,667	63,721	
	21,000	- Divid	054007	00,721	
Total equity and liabilities	128,914	141,207	183,619	194,228	
I otal equity and habilities					

For and on behalf of the Board of Directors

BS LIA

M.R. Jyothy Managing Director DIN: 00571828

Place: Mumbai Date: June 05, 2020

Any

JYOTHY LABS LIMITED (FORMERLY KNOWN AS JYOTHY LABORATORIES LIMITED) STATEMENT OF STANDALONE/CONSOLIDATED FINANCIAL RESULTS

Notes:

11. Statement of Cash Flow:-

(Rs in lacs)

	Year		Year ended		
Particulars	Stand			lidated	
	31.03.2020	31.03.2019	31.03.2020	31.03.2019	
A. CASH FLOWS PROVIDED BY/(USED IN) OPERATING ACTIVITIES:	Audited	Audited	Audited	Audited	
Profit before tax	17.570	22 550	40 4 40		
Adjustments to reconcile profit before tax to net cash flows:	16,560	22,750	18,150	24,304	
Depreciation and impairment of property, plant and equipment	2000	2 702	2.054	2 2 4 4	
Depreciation and impairment of property, plant and equipment	2,888 1,553	2,703	3,254	2,944	
Amortisation and impairment of intangible assets		1 126	1,942	-	
Lease rent income	3,132	3,126	96	113	
Loss / (profit) on sale of fixed assets	(10)	(12)	(1)	(12	
Net change in fair value of financial assets measured at FVTPL	119	48 (12)	32	45	
Profit on sale of current investments	(147)	(159)	(164)	(24	
Finance costs	2,478	2,782	3,288	(171	
Interest income	(277)	(394)	(246)	3,522 (380	
Share of (profit) / loss from investment in partnership firm	2	(32)	(240)	(300	
Unrealised Foreign exchange fluctuation gain (net)	(1)	(2)	(4)	(2	
Investment subsidy income	(72)	(72)	(72)	(72	
Provision for doubtful debts and advances written back	+	(,_,	(,2)	(16)	
Operating profit before working capital changes	26,254	30,726	26,275	30,251	
Movements in working capital:	0,=01	50,720	20,273	50,231	
Decrease / (increase) in loans	(807)	(25)	(148)	64	
Decrease / (increase) in trade receivables	2,871	1,454	3,102	1,421	
Decrease / (increase) in other financials assets	323	147	323	159	
Decrease / (increase) in inventories	(2,195)	(1,368)	(2,278)	(1,394)	
Decrease / (increase) in other assets	366	(1,448)	324	(1,310	
Increase/ (decrease) in trade payables	(4,801)	2,825	(4,905)	2,806	
Increase/ (decrease) in other financial liabilities	(1,803)	1,232	(1,885)	1,286	
Increase/ (decrease) in other liabilities	(434)	501	(428)	496	
Increase / (decrease) in provisions	559	531	625	542	
Cash generated from operations	20,333	34,575	21,005	34,321	
Taxes paid (net)	(3,796)	(4,101)	(3,857)	(4,179)	
Net cash generated from operating activities (A)	16,537	30,474	17,148	30,142	
B. CASH FLOWS PROVIDED BY/(USED IN) INVESTING ACTIVITIES:					
Purchase of fixed assets including capital work-in-progress and capital advances	(3,922)	(3,905)	(4,201)	(3,993)	
Proceeds from sale of fixed assets	34	128	49	162	
Proceeds from sale of Mutual funds	47,909	73,396	58,356	75,407	
Sale of assets held for sale	-	54	20,350	54	
Investment in Mutual funds	(37,750)	(72,850)	(47,750)	(74,347)	
(Investment in)/ maturity proceeds from fixed deposit (net)	484	5,208	545	5,278	
Withdrawal from /(Investment) in partnership firm (net)	143	(1)	-	-	
Interest income received	298	424	246	464	
Lease rent income	10	12	1	12	
Net cash generated from investing activities (B)	7,206	2,466	7,246	3,037	
C. CASH FLOWS PROVIDED BY/(USED IN) FINANCING ACTIVITIES:			(
Finance cost paid	(2,077)	(3,357)	(2,120)	(3,415	
Proceeds from exercise of share options	(2,077)	36		36	
Repayment of Debentures		(20,000)	2 2	(20,000	
Repayment of borrowing	(50,533)	(56,100)	(50,708)	(56,275	
Proceeds from short-term borrowings	51,117	50,000	51,117	50,000	
Payment of principal portion of lease liabilities	(1,686)	-	(2,113)	50,000	
Dividend paid	(22,033)	(1,818)	(22,033)	(1,818	
Dividend tax paid	(4,529)	(374)	(4,529)	(374	
Net cash (used in) financing activities (C)	(29,741)	(31,613)	(30,386)	(31,846	
Net (Decrease)/Increase in cash and cash equivalents (A+B+C)					
Cash and cash equivalents at the beginning of the year	(5,998)	1,327	(5,992)	1,333	
Cash and cash equivalents at the end of the half year	6,684	5,357	7,484	6,151	
Cash and cash equivalents at the end of the nair year Components of cash and cash equivalents	686	6,684	1,492	7,484	
Cash in hand	17	10	47		
Balance with scheduled banks - Current account	16	12	45	53	
- Deposit account	670	6,672	886	6,960	
Cash and cash equivalents considered for cash flow statement	(0)	((0)	561	471	
Casa and cash equivalents considered for easil flow statement	686	6,684	1,492	7,484	

The above Statement of Cash flow has been prepared under the 'Indirect Method' as set out in Ind-AS 7, ' Statement of Cash flows'.

ABS LIA

For and on behalf of the Board of Directors

Place: Mumbai Date: June 05, 2020

dry

M.R. Jyothy Managing Director DIN: 00571828

JYOTHY LABS LIMITED (FORMERLY KNOWN AS JYOTHY LABORATORIES LIMITED) REPORTING OF SEGMENT WISE REVENUE, RESULTS, ASSETS AND LIABILITIES

(Rs in lacs)

	Consolidated							
		Quarter ended	Year ended					
Particulars	31.03.2020	31.12.2019	31.03.2019	31.03.2020	31.03.2019			
	Audited (Note 7)	Unaudited	Audited (Note 7)	Audited	Audited			
Segment Revenue :								
A. Fabric Care	15,574	17,200	18,815	70,800	72,968			
B. Dishwashing	12,705	15,031	16,166	56,670	58,728			
C. Household Insecticides	6,422	4,261	10,022	18,136	22,425			
D. Personal Care	3,020	3,566	4,744	18,042	19,186			
E. Laundry service	963	1,222	999	4,126	4,025			
F. Others	616	799	852	3,343	4,026			
Net Sales	39,300	42,079	51,598	171,117	181,358			
Segment Results:								
Profit / (Loss) before tax and finance cost								
A. Fabric Care	2,797	3,650	4,969	14,253	16,292			
B. Dishwashing	1,587	2,382	1,825	7,974	7,312			
C. Household Insecticides	(687)	(152)	327	(1,644)	330			
D. Personal Care	469	777	1,786	4,783	5,672			
E. Laundry service	(370)	(113)		(1,015)	(960)			
F. Others	(131)	(86)	(78)	(218)	(266)			
Total	3,665	6,458	8,567	24,133	28,380			
Less: (i) Finance cost	(778)	(887)		(3,288)	(3,522)			
(ii) Other unallocable expenditure	(680)	(782)		(2,852)	(1,584)			
(iii) Exceptional Item		, ,	-	(378)	*			
Add: Unallocable Income	116	139	148	535	1,030			
Profit Before Tax	2,323	4,928	7,374	18,150	24,304			
Segment Assets :								
A. Fabric Care	30,746	34,222	31,665	30,746	31,665			
B. Dishwashing	19,726	20,964	18,415	19,726	18,415			
C. Household Insecticides	14,249	15,710	14,930	14,249	14,930			
D. Personal Care	8,114	8,915	6,831	8,114	6,831			
E. Laundry service	12,840	12,909	12,573	12,840	12,573			
F. Others	1,557	1,798	1,383	1,557	1,383			
G. Unallocated assets	96,387	104,898	108,431	96,387	108,431			
Total	183,619	199,416	194,228	183,619	194,228			
Segment Liabilities :								
A. Fabric Care	10,858	9,891	12,584	10,858	12,584			
B. Dishwashing	9,080	8,163	10,816	9,080	10,816			
C. Household Insecticides	5,011	4,176	5,997	5,011	5,997			
D. Personal Care	3,402	3,210	3,294	3,402	3,294			
E. Laundry service	1,422	1,688	765	1,422	765			
F. Others	399	342	550	399	550			
G. Unallocated liabilities	33,495	41,072	29,715	33,495	29,715			
Total	63,667	68,542	63,721	63,667	63,721			

Notes:

- i. Dishwashing includes dish wash scrubber and scrubber steel, dish wash bar, liquid and powder. Fabric Care includes fabric whitener, fabric enhancer, bar soap and detergent powder. Household Insecticides includes mosquito repellent coil, liquid and card and insect repellents. Personal Care includes body soap, face wash, toothpaste, deodorants, talcum powder, after shave, Hand wash and moisturiser. Laundry services includes drycleaning and laundry. Others includes incense sticks, toilet cleaner and floor shine.
- ii. Based on the "management approach" as defined in Ind AS 108 'Operating Segments', the Chief Operating Decision Maker evaluates the Company's performance and allocate resources based on an analysis of various performance indicators by business segments and segment information is presented accordingly.
- iii. Goodwill identifiable to operating segments are included in segment assets, however, where goodwill relates to multiple operating segments and it is not practicable to allocate between segments, it is included in unallocated assets.
- iv. Finance cost is not allocated to any operating segments as the Company reviews the treasury and finance cost at the group level. Accordingly, borrowings are also considered in unallocated liabilities.

For and on behalf of the Board of Directors

M.R. Jyothy Managing Director DIN: 00571828

Place: Mumbai Date: June 05, 2020

din



RESULTS FOR THE QUARTER ENDED 31 MARCH 2020

COVID 19 impacts quarter performance. Essential Hygiene Portfolio to drive future growth.

Mumbai, 5 June 2020 Jyothy Labs Limited (Formerly Jyothy Laboratories Limited) one of the leading Indian FMCG companies announced today its financial results for the quarter ended 31 March 2020. The company delivered sales of ₹ 393 crores, decline of 23.8% against the same period previous year. The company was forecasting mid-single digit sales growth for the quarter before the lockdown. But due to the spread of COVID 19 from mid-March and consequent nationwide lockdown, the business operations were suddenly disrupted across the country.

Our portfolio of Household Insecticide ('HI') and Personal Care ('Soaps') have been impacted greatly because generally in the last fortnight of March our trade partners stock 'HI' products anticipating the onset of high mosquito infestation season from April and also increase their stocks of 'Soaps' anticipating a higher demand with the arrival of Summer season. Due to the nationwide lockdown and disruption of business operations in the last fortnight of March sales of these segments were affected.

During this COVID 19 Phase, we redefined our Go-To-Market Strategy by partnering with alternate distribution channels and last mile delivery partner. We also launched an application 'DISTIMAN' to facilitate orders directly from retailers to distributors. To address the urgent demand of consumers, we have launched in a short time frame a neem based Hand Sanitizer under the brand 'Margo'.

In solidarity with the country's response to COVID-19 relief efforts, the Company has contributed an aggregate sum of Rs.5 Crores to 'PM Cares' and Kerala, Maharashtra and Assam 'CM Funds'. In addition, the senior employees of the Company also contributed their one day's salary to 'PM Cares' Fund.

FINANCIAL HIGHLIGHTS

- Q4 FY2020 Net Sales at Rs. 393 Crores, down by 23.8%. For the Full Year, Net Sales at Rs. 1,711 cr, down by 5.6%
- Q4 FY2020 Net Profit at Rs. 26.6 Crores, down by 60.2%. For the Full Year, Net Profit at 162.6 cr, down by 17.7%

SEGMENT PERFORMANCE

FABRIC CARE - Fabric Whitener, Fabric Enhancer, Bar Soap and Detergent Powder.

Fabric Care sales declined by 17.2% with good performance in each of the brands till lock-down having gained market share across Ujala Fabric Whitener, Ujala IDD, etc. Henko also witnessed good momentum both in Henko Stain Care and Henko Matic with focused marketing initiatives.

DISHWASHIING - Dish Wash Bar, Liquid, Gel, Powder and Scrubbers.

Dishwashing sales declined by 21.4%, however, during the lock-down phase the entire dishwash portfolio has seen a good momentum backed by greater emphasis on hygiene. Exo, India's first Anti-bacterial dishwash brand has seen a good demand with consumers.

HOUSEHOLD INSECTICIDES - Mosquito Repellent Coil, Incense Sticks and Liquid Vaporizer.

Household Insecticides sales declined by 35.9%, because generally in the last fortnight of March our trade partners in North and East India stock 'HI' products anticipating the onset of high mosquito infestation season from April. Due to the nationwide lockdown and disruption of business operations in the last fortnight of March sales of 'HI' were affected. Maxo Genius India first Automatic Liquid Vaporiser Machine continues to gain market share given its unique offering.

PERSONAL CARE - Body Soap, Face Wash, Hand Wash, Sanitizer and Toothpaste.

Personal Care sales declined by 36.4%, as in the last fortnight of March with the arrival of Summer season generally our trade partners stock increased quantity of Soaps anticipating a higher demand; but due to the nationwide lockdown to prevent the spread of COVID 19, sales were disrupted leading to a greater impact on this segment's sale for the quarter ended 31 March 2020.

During the lockdown and going forward, hygiene is of utmost important for consumers. Our Neem based Margo portfolio of Soaps, Facewash, Handwash and Sanitizers have seen increased demand with consumers.

Commenting on the financial performance of Q4 FY2020, Ms. M R Jyothy, Managing Director, Jyothy Labs Limited said "This quarter has brought the onset of an unprecedented global crisis in the form of COVID 19 which has led us to increase our focus on our daily use 'Essential Hygiene Portfolio' as safety, health and hygiene are more critical now than ever. Considering this increased concern for personal hygiene the company launched Neem enriched Handwash and Sanitizer under the brand name 'Margo' which have seen a huge acceptance and demand.

Despite the disruption in operations and sales as a result of the nationwide lockdown since the last fortnight of March 2020, the Company has seen positive sales growth in the month of April and May 2020.

We continue to serve the Indian consumers while scaling up our operations and ensuring health and safety of each of our employees and business partners.

With a strong product portfolio, we are confident we will be able to meet the demands of the consumers and offer them quality products despite all the challenges."

About Jyothy Labs Limited

Jyothy Labs Limited (JLL), one of the leading Indian FMCG companies was founded in 1983 by Mr. M P Ramachandran. Over the years the company has evolved from a single product proprietary firm into a multi brand, BSE & NSE listed company involved in the manufacturing and marketing of products in fabric care, mosquito repellant, surface cleaning, personal care and incense sticks.

The company has multiple leading FMCG brands like Ujala, Maxo, Exo, Henko, Pril, Margo, Mr. White, Neem, Maya and More Light that are well-known and established brands in their respective categories. The company also runs an organized laundry chain which provides 'World class laundry at affordable price at your doorstep' through its subsidiary 'Jyothy Fabricare Services Limited'.





For more information, please contact:

Aniket Singh Chandel

Adfactors PR

M: +91 9987572883

E-mail: aniket.chandel@adfactorspr.com | E-mail: priya.mishra@adfactorspr.com

Priya Mishra

Adfactors PR

M: +91 9769994866



